Shirin Tavakoli

Shirin Tavakoli

Auto-generated profile, based on publicly available information

Shirin Tavakoli

Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
STShirin Tavakoli
Shirin Tavakoli
MSMaryam Samareh-Salavati
Maryam Samareh-Salavati
SAShahrokh Abdolahi
Shahrokh Abdolahi
JVJavad Verdi
Javad Verdi
ISIman Seyhoun
Iman Seyhoun
MAMohammad Ahmadvand
Mohammad Ahmadvand
Background: The activities and functions of natural killer (NK) cells are controlled by a limited repertoire of activating and inhibitory NK receptors. Therefore, blocking inhibitory receptors such as NKG2A using monoclonal antibodies (mAbs) enhances tumor immunity. Method: In this study, we investigated the safety of anti-NKG2A-pretreated NK cells in improving ADCC function to manage hepatocyte carcinoma (HCC). After a conditioning regimen, we initiated a pilot study of expanded donor haploidentical NK cell infusion. The goals were to determine the safety and feasibility. Patients received a fludarabine/cyclophosphamide conditioning followed by adoptive immunotherapy with IL2–activated haploidentical NK cells. Anti-NKG2A pretreated NK cells were infused on days 0, +5, and +10 post-conditioning regimens at a dose of 7 × 108 cells (n=3). The median follow-up was 4 months for all patients. Results: Although all patients were alive at the last follow-up, two of them showed progressive disease and an increase in tumor size. In addition, all patients had a relative decrease in the expression level of an alpha-fetoprotein (AFP) after one month. Conclusion: This study demonstrated the safety and feasibility of infusing high doses of ex vivo expanded NK cells after conditioning with transient side effects.

9 February 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
MSMaryam Samareh Salavatipour
Maryam Samareh Salavatipour
STShirin Tavakoli
Shirin Tavakoli
MBMaryam Barkhordar
Maryam Barkhordar
ISIman Seyhoun
Iman Seyhoun
NVNasim Vousooghi
Nasim Vousooghi
MAMohammad Ahmadvand
Mohammad Ahmadvand
Purpose: Blocking of inhibitory receptors such as NK group-2 member-A (NKG2A) enhances tumor immunity of natural killer (NK) cells. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is an important cytotoxic modality of action of NK cells, which act as a functional bridge between innate and adaptive immunity. Here, we investigated the safety and feasibility of anti-NKG2A antibody-pretreated NK cells combined with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma (GAC). Method: In this pilot study, treatment was initiated with cetuximab-based chemotherapy, followed by three times adoptive administration of anti-NKG2A pretreated NK cells (at doses 7×108 cells/injection) at 5-day intervals in three unresectable and locally advanced GAC patients who enrolled regarding vital signs and clinical characteristics. The clinical signs, laboratory parameters, and CTCAE (Common Terminology Criteria for Adverse Events) were documented for a safety and feasibility assessment. Results: The expanded cells were confirmed to be enriched in NK cells with high expression of CD56 (88.1%) and low expression of NKG2A (0.22%). The combination NK cell therapy was well tolerated, with transient adverse events. All patients were alive at the last follow-up (24 weeks). All patients showed overall decreases in tumor size and CA 19–9 level 4 weeks after combination therapy. However, two patients showed progressive disease (PD) after 12 weeks and the level of CA19-9 was increased in all three patients after 24 weeks. Conclusion: In conclusion, this study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.